March 3, 2026Open Access

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study

Key Points

FCGR3B shows a causal effect on Alzheimer's disease risk, linking it to potential therapies.
The analysis identified FCGR3B as a significant target, while others were not shown to influence risk.
Mendelian randomization was employed to assess the relationship between DMARD targets and Alzheimer's disease.
Further research is necessary to understand FCGR3B's role and validate its therapeutic potential.

Abstract

Our findings suggest a causal effect of FCGR3B on AD risk, but not for the remainder of the analyzed DMARD targets. Further research is recommended to elucidate the causal role of FCGR3B in AD and build upon the current literature on viable AD therapeutic targets.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Christina N. Kushnir

Victoria Taylor-Bateman

Neil M Davies

Journals

Brain Behavior & Immunity - Health

Actions

Institutions

University College London

Norwegian University of Science and Technology

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider